Bon Natural Life (BON) Competitors $1.92 +0.04 (+2.13%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.93 +0.01 (+0.52%) As of 10/24/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BON vs. GRTX, VCNX, ASLN, ZVSA, AKAN, NMTR, HSTO, NKGN, HEPA, and PTPIShould you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Galera Therapeutics (GRTX), Vaccinex (VCNX), ASLAN Pharmaceuticals (ASLN), ZyVersa Therapeutics (ZVSA), Akanda (AKAN), 9 Meters Biopharma (NMTR), Histogen (HSTO), NKGen Biotech (NKGN), Hepion Pharmaceuticals (HEPA), and Petros Pharmaceuticals (PTPI). These companies are all part of the "pharmaceutical products" industry. Bon Natural Life vs. Its Competitors Galera Therapeutics Vaccinex ASLAN Pharmaceuticals ZyVersa Therapeutics Akanda 9 Meters Biopharma Histogen NKGen Biotech Hepion Pharmaceuticals Petros Pharmaceuticals Galera Therapeutics (NASDAQ:GRTX) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends. Which has more risk & volatility, GRTX or BON? Galera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.35, indicating that its stock price is 135% less volatile than the S&P 500. Is GRTX or BON more profitable? Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Bon Natural Life N/A N/A N/A Do analysts prefer GRTX or BON? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Do institutionals & insiders hold more shares of GRTX or BON? 50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to GRTX or BON? In the previous week, Galera Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 3 mentions for Galera Therapeutics and 2 mentions for Bon Natural Life. Galera Therapeutics' average media sentiment score of 0.15 beat Bon Natural Life's score of 0.00 indicating that Galera Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Galera Therapeutics Neutral Bon Natural Life Neutral Which has preferable valuation and earnings, GRTX or BON? Bon Natural Life has higher revenue and earnings than Galera Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.19-0.12Bon Natural Life$23.84M0.65$400KN/AN/A SummaryBon Natural Life beats Galera Therapeutics on 5 of the 9 factors compared between the two stocks. Get Bon Natural Life News Delivered to You Automatically Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BON vs. The Competition Export to ExcelMetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ ExchangeMarket Cap$15.28M$2.34B$8.43B$10.66BDividend YieldN/A4.55%3.07%4.82%P/E RatioN/A17.5619.4030.34Price / Sales0.656.966.44134.75Price / Cash0.1815.1216.4861.44Price / Book0.011.614.946.60Net Income$400K$106.26M$255.94M$276.82M7 Day Performance-4.00%0.71%2.07%2.53%1 Month PerformanceN/A-4.09%-1.38%3.71%1 Year PerformanceN/A-13.44%39.94%33.82% Bon Natural Life Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BONBon Natural Life0.7692 of 5 stars$1.92+2.1%N/AN/A$15.28M$23.84M0.00100Analyst ForecastShort Interest ↓GRTXGalera Therapeutics0.9264 of 5 stars$0.02+4.4%N/A-56.2%$1.26MN/A-0.0530Gap UpVCNXVaccinex0.7965 of 5 stars$0.48flatN/A-74.1%$1.24M$388K-0.0140ASLNASLAN PharmaceuticalsN/A$0.60flatN/AN/A$1.23M$12M-0.0330ZVSAZyVersa TherapeuticsN/A$0.14+3.6%N/A-92.3%$1.07MN/A0.002AKANAkanda0.7736 of 5 stars$2.29+2.7%N/A-60.7%$1.05M$840K0.00110Gap UpHigh Trading VolumeNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A0.0020HSTOHistogenN/A$0.00flatN/AN/A$918K$19K0.0020NKGNNKGen BiotechN/A$0.02+81.8%N/A-94.8%$899KN/A0.00N/AHEPAHepion Pharmaceuticals0.2426 of 5 stars$0.07-10.1%N/A-99.8%$812KN/A-0.0220Negative NewsPTPIPetros PharmaceuticalsN/A$0.02-2.5%N/A-99.8%$729K$5.11M0.0020Gap Down Related Companies and Tools Related Companies Galera Therapeutics Competitors Vaccinex Competitors ASLAN Pharmaceuticals Competitors ZyVersa Therapeutics Competitors Akanda Competitors 9 Meters Biopharma Competitors Histogen Competitors NKGen Biotech Competitors Hepion Pharmaceuticals Competitors Petros Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BON) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bon Natural Life Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Bon Natural Life With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
